SF3B1 and myeloproliferative neoplasm: According to the fifth edition of the WHO classification, MDS/MPN-RS-T, now classified as MDS/MPN with SF3B1 mutation and thrombocytosis (MDS/MPN-T-SF3B1), has the most favorable prognosis among all MDS/MPN types [1].